Emergence of Q493R mutation in SARS-CoV-2 spike protein during bamlanivimab/etesevimab treatment and resistance to viral clearance

J Infect. 2022 Feb;84(2):248-288. doi: 10.1016/j.jinf.2021.08.033. Epub 2021 Aug 23.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Antibodies, Neutralizing
  • COVID-19 Drug Treatment*
  • Humans
  • Mutation
  • SARS-CoV-2 / drug effects
  • SARS-CoV-2 / genetics*
  • Spike Glycoprotein, Coronavirus* / genetics

Substances

  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neutralizing
  • Spike Glycoprotein, Coronavirus
  • spike protein, SARS-CoV-2
  • bamlanivimab
  • etesevimab